(099) Dual Effect of a Serotonin and Dopamine Reuptake Inhibitor (IP2018), and the Search for a Depressive Rat Model with Erectile Dysfunction

Abstract Introduction In patients with major depressive disorder, up to 68% present comorbid sexual dysfunction, which resolves in only 5% 30% of treated antidepressants. Several groups antidepressants negatively affect function. Objective The study investigated whether a newly developed amine transport inhibitor, IP2018, improves depression and erectile function the same dose range. Methods dose-dependent effect IP2018 two different mouse models for depression, forced swim test (mFST) tail suspension (mTST), is reported. male Wistar, Sprague Dawley rats (Flinders Sensitive Line (FSL) Flinders Resistant (FRL)), increases intracavernosal pressure (ICP) mean arterial (MAP) were measured, ratio ICP/MAP was used as measure We induces changes ICP or flow facilitates suboptimal induced by cavernosal nerve electrical stimulation. late procedure performed rest evaluate their Results found that infusion dose-dependently improved mFST more potent than citalopram. At time, higher doses required obtain mTST model, equipotent Infusion low increased number duration spontaneous erections. highest erections similar lowest dose, 5 times higher. (1-30 μM) caused small relaxations isolated corpus cavernosum strips. FSL FRL showed diminished compared control rats. Conclusions has well-known antidepressant drug citalopram depression. on anaesthetized suggests range positive effects both FSL/FRL appear allow one animal model. Disclosure Yes, this sponsored industry/sponsor: Initiator Pharma A/S Clarification Industry funding - investigator initiated executed Any authors act consultant, employee shareholder an industry for: